Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America
Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications DUBLIN, Ohio–(BUSINESS WIRE)–Sep. 6, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent (“LOI”) with Cardinal Health, Inc. (NYSE:CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and […]